Below is Validea's guru fundamental report for TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR) (TEVA). Of the 22 guru strategies we follow, TEVA rates highest using our Acquirer's Multiple Investor model ...

Considering Teva’s extended-release version of Austedo won a key approval in 2023, ramped-up competition in 2025 is something the team at Evercore ISI had anticipated. Even so, this year’s fir ...

AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038. Shares in the brain drug developer ...

Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus TEVA. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Healthcare lease accounting insights: How two organizations got compliant and stay audit-ready all year long Healthcare organizations (HCOs) often hold multiple leases such as those for real estate, ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

After hours: 8:00:00 p.m. EST ...